Calum Archibald MacRae, Ph.D., M.D.
This page shows the publications co-authored by Calum MacRae and Carolyn Ho.
Defining the pathogenicity of DNA sequence variation. Circ Cardiovasc Genet. 2009 Apr; 2(2):95-7.
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
Baseline Characteristics of the VANISH Cohort. Circ Heart Fail. 2019 12; 12(12):e006231.
The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017 May; 187:145-155.
Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013 Jun; 6(3):230-7.
The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication. Mol Genet Genomic Med. 2019 11; 7(11):e940.
A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circ Cardiovasc Genet. 2017 Oct; 10(5).
The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials. 2014 Mar 20; 15:85.
Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2012 Jul 03; 126(1):142-57.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.